Submissions for variant NM_000059.4(BRCA2):c.4561_4563delinsATG (p.Leu1521Met)

dbSNP: rs1064795258

Total submissions: 2

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000485886	SCV000573103	uncertain significance	not provided	2017-02-01	criteria provided, single submitter	clinical testing	This variant is denoted BRCA2 c.4561_4563delCTAinsATG at the cDNA level, p.Leu1521Met (L1521M) at the protein level. The surrounding sequence is TACT[delCTA][insATG]TTGG. This in frame deletion and insertion, also denoted BRCA2 c.4789_4791delCTAinsATG using alternate nomenclature, occurs on the same allele (in cis) and results in the missense change of a Leucine to a Methionine (CTA>ATG). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. Neither BRCA2 c.4561_4563delCTAinsATG nor BRCA2 Leu 1521Met (by this or an alternate nucleotide change) was observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Leucine and Methionine share similar properties, this is considered a conservative amino acid substitution. BRCA2 Leu1521Met occurs at a position that is not conserved and is located in the BRC4, RAD51, and POLH binding domains (Cole 2011, Roy 2012, Buisson 2014). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available information, we consider BRCA2 Leu1521Met to be a variant of uncertain significance.
University of Washington Department of Laboratory Medicine, University of Washington	RCV003157591	SCV003847520	likely benign	Hereditary cancer-predisposing syndrome	2023-03-23	criteria provided, single submitter	curation	Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).